Skip to main content
. 2023 May 4;23:97. doi: 10.1186/s12902-023-01354-x

Fig. 3.

Fig. 3

(A) glucose-lowering effect of A1 and A2 AR antagonist on non-fasting plasma glucose measured before diabetes induction and throughout the weeks of intervention. (B) AUC data for 0–4th week blood glucose are shown. Baseline subtraction for normal control was used to calculate AUC values for all groups, to ensure full treatment benefits are recognised. Values represent mean ± SD for 6 rats. a−e Different alphabets near the lines for a given time (3 A) or bar (3B) for a given time or group respectively represent significance of difference (p < 0.05). * significance of difference P < 0.05 compared to Diabetic control group. NC, Normal Control; DBC, Diabetic Control; DBI, Diabetic + 2-BI; DCA, Diabetic + caffeine; DIS, Diabetic + istradefylline; DPX, Diabetic + DPXPC; DBM, Diabetic Metformin; DGT, Diabetic + pioglitazone